CA19-9-targeting monoclonal antibody clinical trials

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

This study looks at a new drug, BNT329, for people with advanced cancers that have a marker called CA19-9. We want to find out if it's safe, what the best dose is, and if it can help stop cancer growth.